Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,603.00
Bid: 1,602.50
Ask: 1,603.50
Change: -7.00 (-0.43%)
Spread: 1.00 (0.062%)
Open: 1,611.50
High: 1,615.50
Low: 1,601.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 12th Nov 2013 09:20

Accesso: Canaccord Genuity raises target price from 680p to 770p and keeps a buy recommendation.Andor Technology: FinnCap places both its target price (prev.: 390p) and its hold recommendation under review.Babcock International: Jefferies increases target price from 1250p to 1600p retaining a buy recommendation. Investec places its target price (prev.: 1175p) under review, while keeping its add rating.Balfour Beatty: UBS raises target price from 220p to 245p, while downgrading from neutral to sell.British Sky Broadcasting: Alphavalue shifts target price from 1055.2p to 1056.7p and upgrades from add to buy. Credit Suisse reduces target price from 810p to 700p downgrading to underperform.BTG: Investec places its target price (prev.: 472p) under review, while its buy recommendation is kept.Catlin Group: Canaccord Genuity moves target price from 540p to 550p and maintains a buy recommendation.Central Asia Materials: FinnCap initiates with a target price of 222p and a buy recommendation. Canaccord Genuity takes target price from 210p to 245p and stays with its buy recommendation.Chesnara: Canaccord Genuity moves target price from 290p to 300p, while downgrading from buy to hold.Cobham: Deutsche Bank lowers target price from 275p to 270p and maintains a hold recommendation. JP Morgan cuts target price from 310p to 270p reiterating a neutral rating. UBS lowers target price from 305p to 290p leaving its buy recommendation unchanged.Coca-Cola HBC: Goldman Sachs reduces target price from 2100p to 2000p and retains a neutral rating.Craneware: Investec raises target price from 365p to 530p and maintains a buy recommendation.Cropper (James): Westhouse Securities increases target price from 350p to 450p, while downgrading to add.F&C Asset Management: Barclays initiates with a target price of 90p and an underweight rating.GlaxoSmithKline: Panmure Gordon reduces target price from 1850p to 1750p and downgrades from buy to hold.Halfords Group: Deutsche Bank raises target price from 330p to 410p, but still recommends selling.Hunting: FinnCap cuts target price from 900p to 840p, while its hold recommendation is kept.Inmarsat: Alphavalue shifts target price from 729.7p to 732.6p upgrading from reduce to add.Ithaca Energy: Liberum Capital moves target price from 210p to 207p, while staying with its buy recommendation.Lonmin: Deutsche Bank increases target price from 315p to 390p and stays with its hold recommendation. Citi ups target price from 420p to 453p and reiterates a buy recommendation. HSBC raises target price from 485p to 512p leaving its overweight rating unaltered. JP Morgan takes target price from 400p to 430p and keeps an overweight rating.Morgan Advanced Materials: Jefferies lowers target price from 345p to 340p staying with its buy recommendation. JP Morgan moves target price from 335p to 330p, while leaving its overweight rating unchanged. Investec reduces target price from 410p to 390p, while its buy recommendation remains unchanged.Rentokil: Jefferies raises target price from 104p to 116p and keeps a hold recommendation.Rightmove: Panmure Gordon takes target price from 3000p to 3130p maintaining a buy recommendation.Royal Bank of Scotland: Nomura ups target price from 270p to 285p maintaining a reduce rating.RSA Insurance Group: Deutsche Bank shifts target price from 117p to 115p and retains a hold recommendation. Nomura lowers target price fromk 120p to 113p reiterating a neutral rating. JP Morgan cuts target price from 140p to 126p and downgrades to neutral.Shire: Societe Generale increases target price from 3270p to 3615p reiterating a buy recommendation.Smith (WH): Deutsche Bank raises target price from 960p to 1075p maintaining a buy recommendation. UBS increases target price from 750p to 1000p.Speedy Hire: Panmure Gordon shifts target price from 73.6p to 75p and stays with its hold recommendation.Synergy Health: Investec moves target price from 1140p to 1165p and reiterates a buy recommendation.Trifast: N+1 Singer ups target price from 68p to 89p and leaves its buy recommendation unchanged. FinnCap takes target price from 66p to 91p retaining a buy recommendation. Westhouse Securities places both its target price (prev.: 80p) and its buy recommendation under review.Vodafone Group: Espirito Santo ups target price from 215p to 230p and retains a neutral rating.Workspace Group: Liberum Capital takes target price from 546p to 584p and maintains a buy recommendation. Investec ups target price from 500p to 560p retaining a buy recommendation.
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.